# What Other Countries Do
Hook: Every wealthy democracy on earth has solved the drug pricing problem except one. The solutions are not theoretical — they're running, right now, in countries with comparable or better health outcomes than the United States.
The American Exception
The United States is the only wealthy country that does not systematically regulate pharmaceutical prices. Every other OECD nation uses some combination of government negotiation, reference pricing, and health technology assessment to ensure that drug prices reflect value.
The result: Americans pay, on average, 2.56 times more for prescription drugs than citizens of other high-income countries.
Four Models That Work
The UK: NICE and Value-Based Pricing
The National Institute for Health and Care Excellence (NICE) evaluates every new drug against a threshold: does this drug provide enough benefit per dollar spent? If a drug costs more than roughly £20,000–30,000 per quality-adjusted life year (QALY), NICE can reject it. Manufacturers who want access to the UK market must price accordingly.
Germany: Reference Pricing + Free Pricing Window
Germany gives manufacturers one year of free pricing for new drugs, then conducts a benefit assessment. If the new drug isn't demonstrably better than existing alternatives, it's assigned a reference price based on comparable products. This creates a natural ceiling.
Canada: PMPRB Price Review
The Patented Medicine Prices Review Board caps drug prices using an international reference basket — comparing Canadian prices to those in France, Germany, Italy, Sweden, Switzerland, the UK, and the US. Since 2020, the US has been removed from the reference basket because including it inflated the benchmark.
Japan: Biennial Price Revisions
Japan reprices all drugs every two years based on actual market data. If a drug sells significantly above its cost, the price is revised downward. This continuous repricing prevents the kind of unchecked price escalation seen in the US.
Why "Innovation" Is Not the Answer
The pharmaceutical industry's primary argument against price regulation is that lower prices will reduce innovation. This argument has three problems:
First, the countries with price regulation still produce pharmaceutical innovation. Switzerland, Germany, and the UK are home to major pharma companies that innovate under regulated pricing.
Second, much foundational drug research is funded by taxpayers through the NIH, which spends approximately $47 billion annually on medical research. Private companies often build on publicly funded discoveries.
Third, the majority of pharmaceutical company spending goes to marketing and administration, not R&D. In 2022, the top 10 pharma companies spent more on sales and marketing than on research.
The Key Insight
American drug pricing is not the natural state of a free market. It is the result of specific policy choices that other countries have made differently — and better. Every argument that "there's no alternative" is contradicted by the lived experience of every other wealthy democracy on earth. The question isn't whether solutions exist. It's whether we choose to implement them.